FDA grants priority review for Pfizer's Talzenna and Xtandi combo in prostate cancer

July 22, 2026 4:30 PM

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration has accepted for priority review a supplemental New ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found